[9] Yonemaru J, Hashimoto T, Takayanagi D, et al. NTRK fusion-positive colorectal cancer in Japanese population. Pathol Int. 2021;71(5):355-359. doi:10.1111/pin.13082. [10] Liu F, Wei Y, Zhang H, Jiang J, Zhang P, Chu Q. NTR...
1. 周洁.NTRK 融合和TRK抑制剂在非小细胞肺癌中的研究进展[J].中国肿瘤临床.2020;47(12):633-636. 2. Alexander Drilon, et al. Long-term efficacy and safety of larotrectinib in patients with TRK fusion lung cancer. ...
TRK fusion cancerTRK inhibitorsFusions involving TRK protein tyrosine kinases are oncogenic drivers in a variety of tumors in children and adults, with a prevalence of 0.2% in non-small cell lung cancer. Diagnosis can be challenging due to structural features such as NTRK intron length, but ...
参考资料: https://www.onclive.com/view/larotrectinib-demonstrates-favorable-long-term-responses-in-ntrk-fusion-positive-lung-cancer 本文为全球肿瘤医生网原创,未经授权严禁转载
Gao L, Ai X, Lu S. ETV6::NTRK3 gene fusion in a patient with metastatic lung atypical carcinoid successfully treated with repotrectinib: A case report. Lung Cancer. 2024 Jan;187:107443. doi: 10.1016/j.lungcan.2023.107443. Epub 2023 Dec 15. PMID: 38113652....
Case: A 67-Year-Old Man With NTRK Fusion-Positive Metastatic Non-Small Cell Lung Cancer Initial presentation A 67-year old man presented with a 2-month history of cough and dyspnea on exertion PMH/SH: hypercholesterolemia, never smoker PE: right-sided wheezing on auscultation...
home / case-based-peer-perspectives / a-67-year-old-man-with-ntrk-fusion-positive-metastatic-lung-cancer Luis Raez, MD, reviews the case of a 67-year-old man with metastatic non-small cell NTRK gene fusion lung cancer. EP. 1: Case of an NTRK Fusion-Positive Lung...
[1].2021ASCO Abstract9190:Long-term efficacy and safety of larotrectinib in patients with TRK fusion-positive lung cancer. [2].2021ASCO Oral abstract 2002:Efficacy and safety of larotrectinib in adult and pediatric patients with tropomyosin receptor kinase (TRK) fusion-positive primary central ...
NTRK Fusion in Non-Small Cell Lung Cancer: Diagnosis, Therapy, and TRK Inhibitor Resistance. Front Oncol. 2022 Mar 17;12:864666. 2. Cocco E, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol. 2018 Dec;15(12):731-747. 3. O'Haire S...
Frank Weinberg, MD, PhD, physician, researcher, Division of Hematology & Oncology, University of Illinois Health, discusses the treatment options in non–small cell lung cancer (NSCLC) harboring NTRK fusions. NTRK fusion–positive lung cancer is rare, accounting for less than 1% of patients, We...